Obesity and liver disease: the epidemic of the twenty-first century.

Obesity is a rapidly growing health problem that is associated with more than 65 comorbidities and results in substantially increased all-cause mortality. The increase of obesity has played an important role in the increasing prevalence of nonalcoholic fatty liver disease (NAFLD), the most common cause of liver disease in the United States. Understanding the prevalence, comorbidities, and pathogenesis of obesity provides an essential foundation for clinicians who care for individuals with NAFLD.

[1]  J. Rosenstock,et al.  Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes , 2012, Diabetes Care.

[2]  S. Nair,et al.  Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.

[3]  R. Groszmann,et al.  Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis , 2011, Hepatology.

[4]  S. Klein,et al.  Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. , 2013, The Journal of clinical endocrinology and metabolism.

[5]  E. Esrailian,et al.  Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. , 2004, Journal of hepatology.

[6]  C. Bouchard,et al.  Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.

[7]  S. Gortmaker,et al.  Health and economic burden of the projected obesity trends in the USA and the UK , 2011, The Lancet.

[8]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[9]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[10]  P Boffetta,et al.  Metabolic syndrome and hepatocellular carcinoma risk , 2012, British Journal of Cancer.

[11]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[12]  E. Brunt,et al.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. , 2012, Journal of hepatology.

[13]  Jimmy D Bell,et al.  Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study , 2004, Gut.

[14]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[15]  F. Greenway,et al.  Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long‐Term Phentermine Pharmacotherapy for Obesity , 2011, Obesity.

[16]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[17]  P. Misery,et al.  Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. , 2005, Cell metabolism.

[18]  N. Weissman,et al.  A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. , 2011, The Journal of clinical endocrinology and metabolism.

[19]  N. Rasgon,et al.  Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. , 2011, Journal of psychiatric research.

[20]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[21]  J. Marrero,et al.  Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. , 2005, Journal of hepatology.

[22]  R. Leibel,et al.  Changes in energy expenditure resulting from altered body weight. , 1995, The New England journal of medicine.

[23]  A. Lok,et al.  Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. , 2009, Gastroenterology.

[24]  S. Woods,et al.  Central nervous system control of food intake , 2000, Nature.

[25]  G. Loss,et al.  Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.

[26]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[27]  R. Newbold Impact of environmental endocrine disrupting chemicals on the development of obesity , 2010, Hormones.

[28]  M. W. Schwartz,et al.  Central nervous system control of food intake and body weight , 2006, Nature.

[29]  Michael Charlton,et al.  Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain? , 2008, Hepatology.

[30]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[31]  T. Schwartz,et al.  Psychiatric medication‐induced obesity: a review , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[32]  D. Nitka,et al.  The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis , 2010, International Journal of Obesity.

[33]  H. Yoo,et al.  Prevalence of Transaminase Abnormalities in Asymptomatic, Healthy Subjects Participating in an Executive Health-Screening Program , 2003, Digestive Diseases and Sciences.

[34]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.

[35]  J. Proietto,et al.  The defence of body weight: a physiological basis for weight regain after weight loss. , 2013, Clinical science.

[36]  N. Weissman,et al.  Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.

[37]  R. Sturm Increases in clinically severe obesity in the United States, 1986-2000. , 2003, Archives of internal medicine.

[38]  B. Swinburn,et al.  An “ecological” approach to the obesity pandemic , 1997, BMJ.

[39]  K. Flegal,et al.  Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories , 2012 .

[40]  F. Foufelle,et al.  Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c , 2010, Diabetes, obesity & metabolism.

[41]  Claude Bouchard,et al.  Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.

[42]  Deepak L. Bhatt,et al.  Bariatric surgery versus intensive medical therapy in obese patients with diabetes. , 2012, The New England journal of medicine.

[43]  Katsutoshi Tokushige,et al.  Clinical features and outcomes of cirrhosis due to non‐alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C , 2009, Journal of gastroenterology and hepatology.

[44]  D. Matthews,et al.  Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[45]  Benjamin Caballero,et al.  Will All Americans Become Overweight or Obese? Estimating the Progression and Cost of the US Obesity Epidemic , 2008, Obesity.

[46]  K. Gadde,et al.  Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.

[47]  G. Bray,et al.  Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. , 2012, Archives of internal medicine.

[48]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[49]  V. Beral,et al.  Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study , 2010, BMJ : British Medical Journal.

[50]  Katherine M Flegal,et al.  Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. , 2012, JAMA.

[51]  Ralph B D'Agostino,et al.  Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. , 2002, Archives of internal medicine.

[52]  S. Kini,et al.  Nutritional Deficiencies following Bariatric Surgery: What Have We Learned? , 2005, Obesity surgery.

[53]  J. Vallé-Jones,et al.  A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice. , 1983, Pharmatherapeutica.

[54]  S. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[55]  B. Leroux,et al.  Identification of Body Fat Mass as a Major Determinant of Metabolic Rate in Mice , 2010, Diabetes.

[56]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[57]  Daniel B. Jones,et al.  First Report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic Sleeve Gastrectomy has Morbidity and Effectiveness Positioned Between the Band and the Bypass , 2011, Annals of surgery.

[58]  Theo Stijnen,et al.  Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. , 2010, Archives of general psychiatry.

[59]  P. Bedossa,et al.  Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.

[60]  E. Mardis,et al.  An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.

[61]  W. Langhans Role of the liver in the control of glucose‐lipid utilization and body weight , 2003, Current opinion in clinical nutrition and metabolic care.

[62]  N. Stylopoulos,et al.  Roux‐en‐Y Gastric Bypass Enhances Energy Expenditure and Extends Lifespan in Diet‐induced Obese Rats , 2009, Obesity.

[63]  W. Langhans,et al.  Intrameal hepatic-portal infusion of glucose reduces spontaneous meal size in rats , 2001, Physiology & Behavior.

[64]  M. Christensen,et al.  Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.

[65]  William W Eaton,et al.  Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. , 2003, American journal of epidemiology.

[66]  Margaret Anderson,et al.  Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. , 2008, JAMA.

[67]  Lee M. Kaplan,et al.  Conserved Shifts in the Gut Microbiota Due to Gastric Bypass Reduce Host Weight and Adiposity , 2013, Science Translational Medicine.

[68]  C. Weyer,et al.  Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. , 2004, Obesity research.

[69]  F. Greenway,et al.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2010, The Lancet.

[70]  J. Wang,et al.  Body fat topography as an independent predictor of fatty liver. , 1993, Metabolism: clinical and experimental.

[71]  Hyon K. Choi,et al.  Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. , 2007, Archives of internal medicine.

[72]  E. Negri,et al.  Diabetes Mellitus and Cancer Risk in a Network of Case-Control Studies , 2012, Nutrition and cancer.

[73]  P. Even,et al.  Body weight, body composition, and energy metabolism in lean and obese Zucker rats fed soybean oil or butter. , 2002, The American journal of clinical nutrition.

[74]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[75]  Gretchen A. Stevens,et al.  National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants , 2011, The Lancet.

[76]  D. Drucker,et al.  DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks , 2010, Diabetes Care.

[77]  M. Crowell,et al.  Human gut microbiota in obesity and after gastric bypass , 2009, Proceedings of the National Academy of Sciences.

[78]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[79]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, Lancet.

[80]  Y. Iwamoto,et al.  Prevalence of non‐alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[81]  N. Newman,et al.  Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). , 2007, American journal of ophthalmology.

[82]  C. Beglinger,et al.  Bile acids and gut peptide secretion after bariatric surgery: A 1‐year prospective randomized pilot trial , 2013, Obesity.

[83]  N. Nguyen,et al.  Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. , 2008, Journal of the American College of Surgeons.

[84]  Heinrich Taegtmeyer,et al.  Obesity and the risk of heart failure. , 2002, The New England journal of medicine.